Picture For Representation

US drug-maker Gilead Sciences inks pact with 3 Indian drugmakers to produce, sell Remdesivir

New Delhi:¬†US drug-maker Gilead Sciences has signed non-exclusive voluntary licensing agreements with three Indian pharmaceutical companies — Mumbai-headquartered Cipla, Hyderabad-based Hetero Labs and Noida-based Jubilant Life Sciences — who will manufacture and sell the anti-viral drug to treat severe COVID-19 patients. Gilead’s Remdesivir has received emergency use authorisation (EUA) from the US Food and Drug […]